Growth inhibition, drug load, and degradation studies of gelatin/methotrexate conjugates

International Journal of Pharmaceutics

Volumn 308, Issue 1-2, 2006, Pages 90-99

  Ofner III, Clyde M ^a   Pica, Karen ^a,b   Bowman, Bill J ^a,c   Chen, Chao Sheng ^a  

^a UNIVERSITY OF THE SCIENCES   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c MIDWESTERN UNIVERSITY   (United States)

Author keywords

Cathepsin B; Conjugates; Gelatin; HL 60 growth inhibition; Methotrexate release

Indexed keywords

CATHEPSIN B; GELATIN; METHOTREXATE;

ARTICLE; CELL GROWTH; CELL STRAIN HL 60; CONJUGATE; DRUG BINDING; DRUG DEGRADATION; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG RELEASE; DRUG STABILITY; ENZYME DEGRADATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; HYDROLYSIS; LYSOSOME; MOLECULAR WEIGHT; PH; PRIORITY JOURNAL;

ANTIMETABOLITES, ANTINEOPLASTIC; CATHEPSIN B; CELL PROLIFERATION; CULTURE MEDIA, CONDITIONED; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG CARRIERS; DRUG STABILITY; GELATIN; HL-60 CELLS; HUMANS; HYDROGEN-ION CONCENTRATION; METHOTREXATE; SOLUBILITY; TIME FACTORS;

EID: 30744454813     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2005.10.037     Document Type: Article

References (35)

1. J.R. Bertino Ode to methotrexate J. Clin. Oncol. 11 1993 5 14
2. K. Bhalla, A. Hindenberg, R.N. Taub, and S. Grant Isolation and characterization of an anthracycline-resistant human leukemia cell line Cancer Res. 45 1985 3657 3662
3. J. Boratynski, A. Opolski, J. Wietrzyk, A. Gorski, and C. Radzikowski Cytotoxic and antitumor effect of fibrinogen-methotrexate conjugate Cancer Lett. 148 2000 189 195
4. J.D. Borsi, and P.J. Moe New aspects of clinical and cellular pharmacodynamics of methotrexate Acta Paediatr. Scand. 341 Suppl. 1987 4 31
5. B.J. Bowman, and C.M. Ofner III Characterization and in vitro methotrexate release from methotrexate/gelatin conjugates of opposite conjugate bond polarity Pharm. Res. 17 2000 1309 1315
6. B.A. Chabner, D.P. Ryan, L. Paz-Ares, R. Garcia-Carbonero, and P. Calabresi Antineoplastic Agents J.G. Hardmann L.E. Limbird A.G. Gilman Goodman and Gilman's the Pharmacological Basis of Therapeutics 2001 McGraw-Hill New York 1399 1404
7. T.-C. Chou, Q.-H. Tan, and F.M. Sirotnak Quantitation of the synergistic interaction of edatrexate and cisplatin in vitro Cancer Chemother. Pharmacol. 31 1993 259 264
8. W.E. Evans, W.R. Crom, and J.C. Yalowich Methotrexate W.E. Evans J.J. Shentag W.J. Jusko H. Harrison Applied Pharmacokinetics: Principles of Therapeutic Drug Monitoring, Applied Therapeutics 1986 Spokane 1009 1056
9. J. Fitzpatrick, and M. Garnett Studies on the mechanism of action of an MTX-ASA-MoAb conjugate Anti-Cancer Drug Des. 10 1995 11 24
10. G. Halbert, A. Florence, and J. Stuart Characterization of an in vitro drug release and biological activity of methotrexate-bovine serum albumin conjugates J. Pharm. Pharmacol. 39 1987 871 876
11. G. Hartung, G. Stehle, H. Sinn, A. Wunder, H.H. Schrenk, S. Heeger, M. Kranzle, L. Edler, E. Frei, H.H. Fiebig, D.L. Heene, W. Maier-Borst, and W. Queisser Phase I trial of methotrexate-albumin in a weekly intravenous bolus regimen in cancer patients Clin. Cancer Res. 5 1999 753 759
12. R.C. Jackson Biological effects of folic acid antagonist with antineoplastic activity Pharmac. Ther. 25 1984 61 82
13. S.J. Jang, M.G. Wientjes, D. Lu, and J.L.S. Au Drug delivery and transport to solid tumors Pharm. Res. 20 2003 1337 1349
14. A. Kosasih, B.J. Bowman, R.J. Wigent, and C.M. Ofner III Characterization and in vitro release of methotrexate from gelatin/methotrexate conjugates formed using different preparation variables Int. J. Pharm. 204 2000 81 89
15. J.A. Kralovec, M. Singh, M. Mammen, A.H. Blair, and T. Ghose Synthesis of site-specific methotrexate IgG conjugates. Comparison of stability and antitumor activity with active-ester-based conjugates Cancer Immunol. Immunother. 29 1989 293 302
16. Y. Lu, and P.S. Low Folate-mediated delivery of macromolecular anticancer therapeutic agents Adv. Drug Del. Rev. 54 2002 675 693
17. H. Maeda, J. Wu, T. Sawa, Y. Matsumura, and K. Hori Tumor vascular permeability and the EPR effect in macromolecular therapeutics. A review J. Contr. Rel. 65 2000 271 284
18. A. Martin Physical Pharmacy 1993 Lea & Febiger Philadelphia p. 274
19. S. Matsumoto, A. Yamamoto, Y. Takakura, M. Hashida, N. Tanigawa, and H. Sezaki Cellular interaction and in vitro antitumor activity of mitomycin C-dextran conjugate Cancer Res. 46 1986 4463 4468
20. T. Minko, P. Kopeckova, V. Pozharov, and J. Kopecek HPMA copolymer bound adriamycin overcomes MDR1 gene encoded resistance in a human ovarian carcinoma cell line J. Contr. Rel. 54 1998 223 233
21. T. Minko, P. Kopeckova, and J. Kopecek Chronic exposure to HPMA copolymer-bound adriamycin does not induce multidrug resistance in a human ovarian carcinoma cell line J. Contr. Rel. 59 1999 133 148
22. T. Minko, P. Kopeckova, and J. Kopecek Efficacy of the chemotherapeutic action of HPMA copolymer bound doxorubicin in a solid tumor model of ovarian carcinoma Int. J. Cancer 86 2000 108 117
23. T. Minko, P. Kopeckova, V. Pozharav, K.D. Jensen, and J. Kopecek The influence of cytotoxicity of macromolecules and of VEGF gene modulated vascular permeability on the enhanced permeability and retention effect in resistant solid tumors Pharm. Res. 17 2000 505 513
24. G. Murphy, and T. Crabbe Gelatinases A and B A.J. Barrett Methods in Enzymology vol. 248 1985 Academic Press San Diego 473
25. M. Nichifor, E.H. Schacht, and L.W. Seymour Polymeric prodrugs of 5-fluorouracil J. Contr. Rel. 48 1997 165 178
26. B. Nuernberg, M. Kohlbrenner, and R. Faulkner Rabid quantitation of methotrexate and its metabolites in human serum, urine, and bile, using solid-phase extraction and high-performance liquid chromatography J. Chromatogr. 478 1989 476 482
27. C.-H. Pui Childhood leukemias N. Engl. J. Med. 332 1995 1618 1630
28. D. Putnam, and J. Kopecek Polymer conjugates with anticancer activity Adv. Polym. Sci. 122 1995 55 123
29. K. Riebessel, E. Biedermann, R. Loser, N. Breiter, R. Hanselmann, R. Mulhaupt, C. Unger, and F. Kratz Polyethylene glycol conjugates of methotrexate varying in their molecular weight from MW 750 to MW 40 000: synthesis, characterization, and structure-activity relationships in vitro and in vivo Bioconj. Chem. 13 2002 773 785
30. A. Rosowsky, R.A. Forsch, J. Galivan, S.S. Susten, and J.H. Freisheim Regiospecific γ-conjugation of methotrexate to poly(l-lysine), chemical and biological studies Mol. Pharmacol. 27 1985 141 147
31. M.G. Rots, R. Pieters, G.-J.L. Kaspers, C.H. Van Zantwijk, P. Noordhuis, R. Mauritz, A.J.P. Veerman, G. Jansen, and G.J. Peters Differential methotrexate resistance in childhood T- versus common/preB-acute lymphoblastic leukemia can be measured by an in situ thymidylate synthase inhibition assay, but not by the MTT assay Blood 93 1999 1067 1074
32. H.J.-P. Ryser, and W.-C. Shen Conjugation of methotrexate to poly (l-lysine) as a potential way to overcome drug resistance Cancer 45 1980 1207 1211
33. G. Stehle, H. Sinn, A. Wunder, H.H. Schrenk, S. Schutt, and D.L. Heene The loading rate determines tumor targeting properties of methotrexate-albumin conjugates in rats Anti-Cancer Drugs 8 1997 677 685
34. A.H. Thompson, P.A. Vasey, L.S. Murray, J. Cassidy, D. Fraier, E. Frigerio, and C. Twelves Population pharmacokinetics in Phase I drug development: a Phase I study of PK1 in patients with solid tumors Bri. J. Cancer 81 1999 99 107
35. P.A. Trail, D. Willner, S.J. Lasch, A.J. Henderson, S. Hofstead, A.M. Cassazza, R.A. Firestone, I. Hellstrom, and K.E. Hellstrom Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates Science 261 1993 212 215